https://www.nasdaq.com/press-release/agex-therapeutics-to-collaborate-with-university-of-california-irvine-on-research
https://www.nasdaq.com/press-release/agex-therapeutics-licensee-imstem-biotechnology-announces-first-u.s.-multiple
https://www.nasdaq.com/press-release/agex-therapeutics-receives-stock-exchange-deficiency-letter-2021-11-23
https://www.nasdaq.com/press-release/agex-therapeutics-reports-third-quarter-2021-financial-results-2021-11-12
https://www.nasdaq.com/press-release/agex-therapeutics-to-collaborate-with-university-of-california-irvine-on-research
https://www.nasdaq.com/press-release/agex-therapeutics-licensee-imstem-biotechnology-announces-first-u.s.-multiple
https://www.nasdaq.com/press-release/agex-therapeutics-receives-stock-exchange-deficiency-letter-2021-11-23
https://www.nasdaq.com/press-release/agex-therapeutics-reports-third-quarter-2021-financial-results-2021-11-12
https://www.nasdaq.com/press-release/agex-announces-preprint-article-relating-to-regeneration-aging-and-cancer-2021-03-12
https://www.nasdaq.com/press-release/agex-therapeutics-to-collaborate-with-the-ohio-state-university-to-generate-proof-of
https://www.nasdaq.com/press-release/agex-therapeutics-and-lygenesis-to-negotiate-merger-agreement-2021-03-02
https://www.nasdaq.com/press-release/agex-therapeutics-inc.-announces-that-its-annual-meeting-of-stockholders-will-be
https://www.nasdaq.com/press-release/agex-therapeutics-reports-third-quarter-2020-financial-results-and-provides-business
https://www.nasdaq.com/press-release/agex-therapeutics-sublicenses-stem-cell-line-esi-053-to-imstem-biotechnology-for
https://www.nasdaq.com/press-release/agex-therapeutics-and-lineage-cell-therapeutics-announce-expansion-of-agreement
https://www.nasdaq.com/press-release/agex-therapeutics-reports-second-quarter-2020-financial-results-and-provides-business
https://www.nasdaq.com/press-release/agex-therapeutics-and-pluristyx-announce-manufacturing-marketing-and-distribution
https://www.nasdaq.com/press-release/agex-therapeutics-receives-stock-exchange-deficiency-letter-2020-06-05
https://www.nasdaq.com/press-release/agex-therapeutics-and-imstem-biotechnology-sign-non-binding-letter-of-intent
https://www.nasdaq.com/press-release/agex-therapeutics-and-sernova-to-collaborate-to-engineer-universal-locally-immune
https://www.nasdaq.com/press-release/agex-therapeutics-inc.-appoints-andrea-park-as-chief-financial-officer-2020-05-21
https://www.nasdaq.com/press-release/agex-therapeutics-reports-first-quarter-2020-financial-results-and-provides-business
https://www.nasdaq.com/press-release/agex-therapeutics-announces-reduction-in-projected-cash-expenditures-2020-05-01
https://www.nasdaq.com/press-release/agex-therapeutics-reports-fourth-quarter-and-annual-2019-financial-results-and
https://www.nasdaq.com/press-release/agex-therapeutics-licensee-imstem-biotechnology-announces-fda-has-lifted-the-hold-and
https://www.nasdaq.com/press-release/agex-therapeutics-researchers-publish-paper-on-the-age-reprogramming-of-super
https://www.nasdaq.com/press-release/agex-therapeutics-to-collaborate-with-university-of-california-irvine-on-neural-stem
https://www.nasdaq.com/press-release/agex-therapeutics-enters-research-collaboration-with-japanese-biopharma-company-to
https://www.nasdaq.com/press-release/agex-therapeutics-to-participate-at-four-conferences-in-january-2020-2020-01-14
https://www.nasdaq.com/press-release/agex-therapeutics-announces-drawdown-of-second-tranche-of-loan-facility-from
https://www.nasdaq.com/press-release/agex-therapeutics-issues-year-end-letter-to-shareholders-2019-12-09
https://www.nasdaq.com/press-release/agex-therapeutics-reports-third-quarter-2019-financial-results-and-provides-business
